Johnson & Johnson inventory (NYSE: JNJ) is scheduled to report its Q1 2021 outcomes on Tuesday, April 20. We anticipate J&J to report revenues and earnings barely beneath the consensus estimates. The prescription drugs gross sales can be pushed by market share features for Imbruvica, Darzalex, and Stelara, greater than offsetting the decline in gross sales of Zytiga and Remicade, owing to biosimilar competitors. Medical Gadgets enterprise was hit final yr as a consequence of fewer procedures, a development that has reversed over the latest quarters. Nonetheless, section development could possibly be hit given the surge in Covid-19 circumstances from newer variants throughout the globe. We anticipate the corporate to navigate effectively based mostly on these developments over the most recent quarter. Equally, Covid-19 disruptions seemingly weighed on the corporate’s client healthcare enterprise as effectively.
J&J started the rollout of its single-dose Covid-19 vaccine within the U.S. in early March 2021, and its near-term provide is anticipated to say no, as the corporate faces some manufacturing challenges. That stated, the corporate says that it’s on observe to ship 100 million doses to the USA authorities by the top of Could. Individually, the European Union’s well being company is investigating experiences that just a few folks developed severe blood clots after receiving J&J’s Covid-19 vaccine within the U.S. Nonetheless, we predict it’s unlikely that it will impression the eventual rollout of the shot which was just lately permitted to be used within the E.U. Whereas J&J has been in focus over its vaccine, there may be not a lot from a inventory worth appreciation standpoint, provided that it’s a not-for-profit product for the corporate. General, oncology and immunology medication would be the key development driver for J&J within the close to time period, in our view. Our evaluation on J&J Vaccine Updates offers extra particulars.
Whereas we consider J&J will put up Q1 outcomes barely beneath the road expectation, JNJ inventory stays enticing on the present ranges. Our forecast signifies that J&J’s valuation is round $196 per share, which is 22% increased than the present market worth of round $160. Our interactive dashboard evaluation on Johnson & Johnson Pre-Earnings has further particulars.
(1) Revenues anticipated to be barely beneath the consensus estimates
Trefis estimates J&J’s Q1 2021 revenues to be round $21.9 Bil, barely beneath the $22.zero Bil consensus estimate. J&J in 2020 noticed a decline in medical units income, as a consequence of deferment of elective surgical procedures given the unfold of Covid-19. Nonetheless, the decline was greater than offset by continued development in prescription drugs gross sales pushed by its oncology and immunology medication. The corporate’s three medication – Stelara, Imbruvica, and Darzalex – garnered $16 billion in gross sales in 2020, or one-fifth of the corporate’s whole revenues. Prescription drugs section will seemingly stay the important thing development driver for J&J in Q1 as effectively. Our dashboard on Johnson & Johnson Revenues presents extra particulars on the corporate’s segments.
2) EPS prone to be beneath the consensus estimates
J&J’s Q1 2021 adjusted earnings per share (EPS) is anticipated to be $2.28 per Trefis evaluation, 2% beneath the consensus estimate of $2.33. J&J’s adjusted web revenue of $5.zero Bil in This fall 2020 mirrored a modest 1% y-o-y drop. This may be attributed to over 200 bps decline in web margins, partly owing to elevated R&D investments. Nonetheless, as the corporate sees a rebound in gross sales, the margins are anticipated to enhance, bolstering the general earnings development in 2021. For the full-year 2021, we anticipate the adjusted EPS to be increased at $9.52 in comparison with $8.03 in 2020.
(3) Inventory worth estimate 22% increased than the present market worth
Going by our Johnson & Johnson’s Valuation, with an EPS estimate of round $9.52 and a P/E a number of of round 21x in 2021, this interprets right into a worth of $196, which is 22% above the present market worth of round $160. At present ranges of $160, JNJ inventory is buying and selling at 17x its anticipated EPS of $9.52 in 2021, and the 17x determine compares with ranges of 20x seen as just lately as late 2020, implying there may be extra room for development for JNJ inventory.
Observe: P/E Multiples are based mostly on Share Worth on the finish of the yr and reported (or anticipated) Adjusted Earnings for the complete yr
Whereas JNJ inventory could also be undervalued, 2020 has created many pricing discontinuities which might supply enticing buying and selling alternatives. For instance, you’ll be shocked how counter-intuitive the inventory valuation is for Johnson & Johnson vs Regeneron Prescription drugs.
See all Trefis Worth Estimates and Obtain Trefis Knowledge right here
What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Groups | Product, R&D, and Advertising Groups
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially mirror these of Nasdaq, Inc.